Dr. Niclas Kneisel

Responsible for collaborations with international leading research institutes Involved in all Business Development discussions and negotiations for the out-licensing of proprietary compounds Taking part in strategic planning of clinical trial development and marketing strategies including HTA and regulatory discussions Deep insights into biologics drug development in the fields of immune-oncology and haematology Competitor Intelligence and providing insights in strategic development discussions

Molecular characterisation of the branched-chain amino acid transaminase 1 (BCAT1) in glioblastoma, mammary carcinoma and AML. Focus on carbon metabolism, histone modifications and cell signalling. Introduction into bioinformatic analysis using R.

Molecular and metabolic characterisation of BCAT1 in glioblastoma and mammary carinoma. Integration of the results of metabolomic tracings into cell signalling and epigenetic contexts. Focus on hypoxic signalling, maintenance of proliferation and DNA methylation.

Alzheimer's Disease, Mitochondrial Calcium homeostasis, Viral systems for reversible shut-down of synaptic transmission, Excitotoxicity, FRET indicators, Final grade: 1.0